Geert-Jan Mulder, MD, co-founded Forbion and serves as a Managing Partner for the fund. Geert-Jan is an experienced life sciences investor who has led successful investments and served on the boards of several portfolio companies including Sanifit (sold to Vifor in 2021), KaNDy Therapeutics (sold to Bayer in 2020), Enterprise Therapeutics (sold to Roche in 2020), Promedior (sold to Roche in 2020), Exsosome (sold to Bio-Techne in 2018), bluebirdbio (IPO on Nasdaq 2013: BLUE), Acorda (IPO on Nasdaq 2006: ACOR), PanGenetics (sold to Abbott in 2009) and Transave (reverse-merged with Insmed, listed on Nasdaq in 2010: INSM).
Alongside his work on the boards of Forbion companies, Geert-Jan works closely with various portfolio company management teams, assisting with clinical development strategies and regulatory matters such as IND/NDA filings, Special Protocol Approval (SPA), and US/EU Orphan designations for several products. In this capacity, Geert-Jan has authored and co-authored several scientific publications from Forbion and Forbion-portfolio companies.
Before joining the venture industry in 2001, Geert-Jan spent two years as a resident in obstetrics and gynaecology (OBGYN) at the University Medical Center of Utrecht. He has also spent several years in the pharmaceutical industry in clinical development and global media marketing for Searle (now Pfizer) and Byk Gulden (now Takeda).